January 8, 2024 7:56am

The name of the game this week, dominates institution’s attention …

Who will have a seat when the presentations begin, which will benefit from the investment gamut after when the music stops?

Financing: Solid Biosciences (SLDB) Announces $109 Million Private Placement … https://www.regmedinvestors.com/articles/13275

Pre-open Indications: 5 Positive and 2 Negative Indications

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

The pre-open Dow futures are DOWN -0.45% or (-171 points), the S&P futures are DOWN -0.07% or (-3 points) as the Nasdaq futures are DOWN -0.01% (-1 points)

U.S. stock futures were down and still fluctuating  Monday morning,

European markets were lower,

Asia Pacific markets were down with Japan closed for a public holiday

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Friday, indexes closed barely up; the Dow closed UP +25.77 points or +0.07%, the S&P closed UP +8.56 points or +0.18% while the Nasdaq closed UP +13.77 points or +0.09%.

For the week, the Dow dropped -1.5%, the S&P 500 slid -0.6% while the Nasdaq fell -3.25%.

“This week, traders will get greater clarity into the path of rate cuts from the central bank. The December consumer price index is set for release Thursday, while the producer price index is due out on Friday, will show whether the Fed’s efforts to bring inflation down to its 2% are taking hold.” <CNBC>

 

Friday, RegMed Investors (RMi) Closing Bell: “liquefying the sector from the pre-open thesis. Economics still focus and direct our sector and markets.”  … https://www.regmedinvestors.com/articles/13274   

 

Q1/24: 1 holiday, 2 negative and 2 positive closes

Q4:

  • December – 1 holiday, 10 positive and 10 negative closes
  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 1 sick day, 9 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Friday’s, Thursday, Wednesday, Tuesday’s closing price after Monday’s holiday and closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed Friday down -$2.93 after Thursday’s +$1.67, Wednesday’s -$4.29, Tuesday’s +$3.52 and Monday’s holiday with a positive +$3.41 pre-open indication.

  • ALNY announced its preliminary* Q4 and FY23 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches. at December 31, 2023, Alnylam had preliminary cash, cash equivalents, and marketable securities of approximately $2.4 billion, as compared to $2.2 billion at December 31, 2022.

Beam Therapeutics (BEAM) closed Friday up +$0.05 with a positive +$0.53 or +2.03% pre-open indication.

Caribou Bioscience (CRBU) closed Friday down -$0.34 after Thursday’s -$0.04 with a positive +$0.10 or +2.07% pre-open indication.

CRISPR Therapeutics (CRSP) closed Friday down -$1.27 after Thursday’s -$0.62, Wednesday’s -$3.50, Tuesday’s +$3.46 and Monday’s holiday with a positive +$0.11 or +0.18% pre-open indication

Verve Therapeutics (VERV) closed Friday down -$0.29 after Thursday’s +$0.61 to $13.61, after Wednesday’s -$1.00, Tuesday’s +$0.06 and Monday’s holiday with a positive +$0.17 or +1.28% pre-open indication

 

Negative Indications:

Friday’s Thursday, Wednesday, Tuesday’s closing price after Monday’s holiday and closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

AxoGen (AXGN) closed up +$1.80 with AXGN announcing POSITIVE preliminary unaudited Q4 and FY2023 revenue after Thursday’s +$0.12 with a negative -$0.04 or -0.47% pre-open indication.

Sage Therapeutics (SAGE) closed up +$0.34 after Thursday’s -$0.54, Wednesday’s -$0.81, Tuesday’s +$0.81 and Monday’s holiday with a negative -$0.17 or -0.79% aftermarket indication

 

The BOTTOM LINE: It was a tough start in 2024 as the cell and gene therapy sector split pos/neg closes …

Q1/24 – January

  • Friday closed negative with 12 incliners, 23 decliners and 0 flat
  • Thursday closed positive with 22 incliners, 12 decliners and 1 flat
  • Wednesday closed negative with 6 incliners, 29 decliners and 0 flat
  • (1/2) Tuesday closed positive with 21 incliners, 14 decliners and 0 flat

As the stock market got off to a rough start in 2024, with the major indexes snapping a nine-week losing streaks.

 

The real questions is … will institutions followed by uncle algo and his electronic traders create buying opportunities from the JP Morgan Healthcare conference.

 

My opinion from 12/29/23 ended with “my message of: Looking toward 2024 with one word – recalibration i.e., a change in the way you do or think about something – markets and the cell and gene therapy sector.”

  • I STILL believe the sector is headed into “correction” which means that investors should remain cautious as “our” universe skips into Q4 and 2023’s end earnings’ LPS (loss-per-share) reporting.

 

News, financings, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!

  • It's also a good idea to take some profits, especially if you didn't do so in past sessions. <IBD>

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.